RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
ConditionMelanoma Advanced
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorFudan University
About this trial
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Eligibility criteria
Qualifiers
Aged ≥18 years (inclusive), male or female;
Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
Prior genetic testing results showing positive NRAS mutation;
Patients who have failed prior anti-PD-1/PD-L1 therapy;
Disqualifiers
Currently participating in other clinical trials of drugs;
Patients who are pregnant or breastfeeding;
Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;
Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.
Trial design
Treatments tested in this trial
- tunlametinib
Treatment groups
110 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov